Free Trial

AstraZeneca (AZN) Competitors

AstraZeneca logo
$70.96 +0.55 (+0.78%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$70.56 -0.40 (-0.57%)
As of 05:41 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

AZN vs. NVO, NVS, SNY, GSK, TAK, ARGX, ONC, BNTX, TEVA, and SMMT

Should you be buying AstraZeneca stock or one of its competitors? The main competitors of AstraZeneca include Novo Nordisk A/S (NVO), Novartis (NVS), Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), argenx (ARGX), Beigene (ONC), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

AstraZeneca vs.

Novo Nordisk A/S (NYSE:NVO) and AstraZeneca (NASDAQ:AZN) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Novo Nordisk A/S pays an annual dividend of $1.63 per share and has a dividend yield of 2.3%. AstraZeneca pays an annual dividend of $2.06 per share and has a dividend yield of 2.9%. Novo Nordisk A/S pays out 48.2% of its earnings in the form of a dividend. AstraZeneca pays out 82.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.

Novo Nordisk A/S has higher revenue and earnings than AstraZeneca. Novo Nordisk A/S is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Novo Nordisk A/S$303.14B1.04$14.64B$3.3820.83
AstraZeneca$54.98B4.00$7.04B$2.4928.50

11.5% of Novo Nordisk A/S shares are held by institutional investors. Comparatively, 20.4% of AstraZeneca shares are held by institutional investors. 0.1% of Novo Nordisk A/S shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Novo Nordisk A/S has a net margin of 34.81% compared to AstraZeneca's net margin of 13.01%. Novo Nordisk A/S's return on equity of 84.68% beat AstraZeneca's return on equity.

Company Net Margins Return on Equity Return on Assets
Novo Nordisk A/S34.81% 84.68% 26.29%
AstraZeneca 13.01%32.23%12.31%

Novo Nordisk A/S currently has a consensus price target of $135.00, indicating a potential upside of 91.79%. AstraZeneca has a consensus price target of $88.00, indicating a potential upside of 24.01%. Given Novo Nordisk A/S's higher probable upside, equities analysts plainly believe Novo Nordisk A/S is more favorable than AstraZeneca.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Novo Nordisk A/S
2 Sell rating(s)
5 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.38
AstraZeneca
0 Sell rating(s)
1 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.10

Novo Nordisk A/S received 371 more outperform votes than AstraZeneca when rated by MarketBeat users. Likewise, 61.74% of users gave Novo Nordisk A/S an outperform vote while only 60.00% of users gave AstraZeneca an outperform vote.

CompanyUnderperformOutperform
Novo Nordisk A/SOutperform Votes
434
61.74%
Underperform Votes
269
38.26%
AstraZenecaOutperform Votes
63
60.00%
Underperform Votes
42
40.00%

Novo Nordisk A/S has a beta of 0.65, indicating that its share price is 35% less volatile than the S&P 500. Comparatively, AstraZeneca has a beta of 0.4, indicating that its share price is 60% less volatile than the S&P 500.

In the previous week, Novo Nordisk A/S had 17 more articles in the media than AstraZeneca. MarketBeat recorded 45 mentions for Novo Nordisk A/S and 28 mentions for AstraZeneca. AstraZeneca's average media sentiment score of 1.20 beat Novo Nordisk A/S's score of 0.82 indicating that AstraZeneca is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Novo Nordisk A/S
27 Very Positive mention(s)
6 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive
AstraZeneca
18 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Novo Nordisk A/S beats AstraZeneca on 13 of the 21 factors compared between the two stocks.

Get AstraZeneca News Delivered to You Automatically

Sign up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AZN vs. The Competition

MetricAstraZenecaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$220.07B$6.51B$5.38B$8.46B
Dividend Yield2.96%2.65%5.28%4.17%
P/E Ratio31.408.7727.0319.89
Price / Sales4.00254.76401.79138.33
Price / Cash11.7965.8538.2534.64
Price / Book5.386.426.784.56
Net Income$7.04B$142.98M$3.22B$248.06M
7 Day Performance1.84%3.41%1.72%2.15%
1 Month Performance1.47%2.10%6.99%9.09%
1 Year Performance-7.39%-0.68%19.63%9.75%

AstraZeneca Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AZN
AstraZeneca
2.8315 of 5 stars
$70.96
+0.8%
$88.00
+24.0%
-9.7%$220.07B$54.98B31.4083,500Positive News
NVO
Novo Nordisk A/S
4.7092 of 5 stars
$67.26
-1.3%
$135.00
+100.7%
-48.3%$301.83B$303.14B20.4454,400Gap Up
NVS
Novartis
1.5677 of 5 stars
$112.77
+0.2%
$123.38
+9.4%
+12.4%$238.21B$53.22B19.18101,700Positive News
SNY
Sanofi
3.9215 of 5 stars
$51.98
-1.0%
$63.33
+21.8%
+7.9%$131.32B$45.17B20.8891,600Trending News
GSK
GSK
1.5898 of 5 stars
$38.70
-0.6%
$40.58
+4.9%
-12.6%$79.84B$31.53B24.3490,100Positive News
Analyst Revision
Gap Up
TAK
Takeda Pharmaceutical
3.4979 of 5 stars
$14.58
+1.1%
N/A+11.9%$46.38B$4.58T36.4447,300Positive News
ARGX
argenx
3.3509 of 5 stars
$587.61
+1.1%
$698.11
+18.8%
+57.9%$35.88B$2.58B-667.74650Positive News
ONC
Beigene
2.8381 of 5 stars
$241.43
+1.1%
$319.00
+32.1%
N/A$23.91B$4.18B-29.309,000News Coverage
BNTX
BioNTech
2.5489 of 5 stars
$98.68
-0.4%
$141.73
+43.6%
+1.7%$23.72B$2.75B-46.993,080
TEVA
Teva Pharmaceutical Industries
3.1328 of 5 stars
$16.95
+0.0%
$24.43
+44.2%
+6.7%$19.21B$16.62B-11.6936,800Positive News
Gap Down
SMMT
Summit Therapeutics
2.8875 of 5 stars
$25.85
+0.3%
$37.40
+44.7%
+658.6%$19.20B$700,000.00-92.32110Positive News

Related Companies and Tools


This page (NASDAQ:AZN) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners